Company appoints renowned key opinion leaders
in liver fibrosis, Scott Friedman,
MD, and Ira Tabas, MD,
PhD
PHILADELPHIA, Aug. 6, 2024
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM)
("Carisma" or the "Company"), a clinical-stage biopharmaceutical
company focused on discovering and developing innovative
immunotherapies, today announced the appointment of Dr.
Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board
(SAB). Dr. Friedman and Dr. Tabas bring extensive expertise and
pioneering contributions in liver fibrosis, which will be
instrumental as Carisma continues its program to develop
transformative treatments for patients.
"It is an honor to welcome Dr. Friedman and Dr. Tabas to our
Scientific Advisory Board," said Steven
Kelly, President and Chief Executive Officer of Carisma.
"Their extensive experience and groundbreaking research in liver
fibrosis will significantly enhance our efforts in developing
innovative engineered macrophage therapies for advanced liver
disease. We are excited to collaborate with them and benefit from
their profound expertise."
About Scott Friedman,
MD
Dr. Friedman is the Chief Emeritus of Liver Diseases at the
Icahn School of Medicine at Mount
Sinai. He is renowned for his pioneering research into the
underlying causes of fibrosis associated with chronic liver
disease, which affects millions of patients worldwide. Dr. Friedman
was among the first to isolate and characterize the hepatic
stellate cell, the key cell type responsible for scar production in
the liver.
Dr. Friedman is widely recognized as a dynamic and respected
author, with over 300 peer-reviewed publications. Throughout his
career, he has mentored more than 100 postdoctoral fellows and
students. He is also a past president of the American Association
for the Study of Liver Diseases (AASLD) and a Fellow of the
American Association for the Advancement of Science. In recognition
of his outstanding contributions to the understanding of liver
disease and its treatment, Dr. Friedman received the Saul Horowitz,
Jr. Outstanding Alumnus Award from Mount Sinai School of Medicine
in 1993 and the International Hans Popper Award from the Falk
Foundation in Freiburg, Germany,
in 2003. He also received the Distinguished Achievement Awards from
the European Association for the Study of Liver (EASL), the AASLD,
and the American Liver Foundation. He currently consults for
approximately 25 companies in the liver disease space.
Dr. Friedman received his MD from the Icahn School of Medicine
at Mount Sinai in New York City. He completed his Internal
Medicine residency at Beth Israel Hospital, Harvard Medical School in Boston, and his Gastroenterology Fellowship at
the University of California, San
Francisco.
About Ira Tabas, MD,
PhD
Dr. Tabas is the Richard J. Stock Professor and Vice-Chair of
Research in the Department of Medicine and Professor of Pathology
and Cell Biology (in Physiology and Cellular Biophysics) at
Columbia University in New York City. Dr. Tabas has extensively
studied multiple pathways involved in metabolic
dysfunction-associated steatohepatitis (MASH) fibrosis, focusing on
crosstalk between hepatocytes, liver macrophages, and hepatic
stellate cells. His work has revealed key roles for a
transcriptional regulator called TAZ and for the process of whereby
macrophages clear dead hepatocytes in MASH liver (efferocytosis).
Both of these discoveries have led to patent applications and drug
development efforts led by pharma and biotech companies. Dr. Tabas
also studies the mechanism of atherosclerosis and is currently
investigating mechanisms and therapeutic targets that are common
between MASH and atherosclerosis.
Dr. Tabas has lectured worldwide and published approximately 300
original research articles and reviews in prestigious journals. He
has also served on the Board of Reviewing Editors for the journal
Science. Dr. Tabas has been elected to both the Society for
Clinical Investigation and the Association of American Physicians.
Dr. Tabas' honors include the American Heart Association
Established Investigator Award, the Columbia
University Doctor Harold and Golden
Lamport Research Award, the American Heart Association/ATVB
Council Special Recognition Award, the Richard J. Stock
Professorship in the Department of Medicine of Columbia University, and the 2011 Alumni
Achievement Award from Washington
University School of Medicine.
Dr. Tabas received his MD and PhD degrees from Washington University in St. Louis and completed his residency in
Internal Medicine and a fellowship in Endocrinology/Metabolism at
Columbia Presbyterian Medical Center in New York City, with board certification in
both disciplines.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-expansion-of-its-scientific-advisory-board-302214945.html
SOURCE Carisma Therapeutics Inc.